Hovione steps up manufacture of TwinCaps inhalers for flu drug
This article was originally published in Scrip
Executive Summary
The Portuguese manufacturer Hovione plans to move to large-scale manufacture of its TwinCaps inhaler, following its use in Phase III trials of Daiichi Sankyo/Biota's long-acting neuraminidase inhibitor, laninamivir (CS-8958).